Xilio Therapeutics Inc (XLO)
1.14
+0.06
(+5.56%)
USD |
NASDAQ |
May 17, 16:00
1.14
0.00 (0.00%)
After-Hours: 20:00
Xilio Therapeutics SG&A Expense (Annual): 27.00M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 27.00M |
| December 31, 2022 | 29.95M |
| December 31, 2021 | 23.86M |
| Date | Value |
|---|---|
| December 31, 2020 | 10.65M |
| December 31, 2019 | 4.771M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
4.771M
Minimum
2019
29.95M
Maximum
2022
19.24M
Average
23.86M
Median
2021
SG&A Expense (Annual) Benchmarks
| Gilead Sciences Inc | 6.09B |
| FibroGen Inc | 115.25M |
| Avalo Therapeutics Inc | 10.30M |
| IGM Biosciences Inc | 50.07M |
| AEON Biopharma Inc | 13.68M |